📑 On this page

 

prostate cancer

Introduction: Prostate cancer develops in the prostate gland, a small walnut-sized organ in the male reproductive system that helps make semen. It is one of the most frequently diagnosed cancers in men, and while most cases grow slowly, some can spread beyond the prostate. This article explains what prostate cancer is, where the prostate is located, and how common the disease is in the United States. It also outlines established risk factors such as age, family history, and race, describes typical urinary symptoms and signs of advanced disease, and summarizes the main tests used for detection including PSA blood tests and biopsies. Finally, it reviews current treatment approaches ranging from active surveillance to surgery, radiation, and hormone-based therapies.

What Is Prostate Cancer and Who Is at Risk?

The prostate sits below the bladder and surrounds the urethra

Prostate cancer forms in the tissues of the prostate, a gland that sits just below the bladder and in front of the rectum. It surrounds part of the urethra, the tube that carries urine out of the body, and produces fluid that becomes part of semen. Because of this location, changes in the prostate often affect urination first. Other than skin cancer, prostate cancer is the most common cancer in men in the United States. About one in eight men will receive a diagnosis during their lifetime, and most cases occur in older men. Roughly six in ten cancers are found in men aged 65 or older, and diagnosis is rare before age 40, with the average age at diagnosis around 67. Although it is the second-leading cause of cancer death in American men behind lung cancer, most men diagnosed do not die from the disease, and death rates have fallen by about half since the early 1990s due to earlier detection and improved treatment. Risk increases with several well-documented factors. Age is the strongest, with risk rising sharply after 50. A family history of prostate cancer in a father, brother, or son also raises risk. In the United States, the disease occurs more often in African American men than in White men, and African American men are more likely to die from it. Other factors studied include male hormones such as testosterone and its conversion to dihydrotestosterone, high intake of vitamin E supplements, high-dose folic acid supplements, and diets high in dairy foods and calcium. Early prostate cancer often causes urinary changes that overlap with benign prostatic hyperplasia. These can include trouble starting the flow of urine, needing to urinate frequently especially at night, difficulty emptying the bladder completely, and a weak or interrupted stream. When cancer is advanced, men may notice persistent pain in the back, hips, or pelvis, and symptoms related to anemia such as shortness of breath, unusual tiredness, fast heartbeat, dizziness, or pale skin.

• Age, family history, and race are established risk factors, with African American men facing higher incidence and mortality.
• The prostate sits below the bladder and surrounds the urethra, which explains why urinary symptoms are often the first clue.
• Most cases are diagnosed in men over 65, and about one in eight men in the US will develop prostate cancer in their lifetime.

How Prostate Cancer Is Detected and Treated

PSA testing and imaging help guide prostate cancer diagnosis

Detection begins with a medical history and physical exam, followed by tests that look directly at the prostate and measure blood markers. A digital rectal exam allows a clinician to feel the prostate through the rectal wall for lumps or abnormal areas. The prostate-specific antigen test measures PSA in the blood; levels may be higher in men with prostate cancer, though infection, inflammation, or benign enlargement can also raise PSA. Imaging can help clarify findings. Transrectal ultrasound uses sound waves to create pictures of the prostate and is often used to guide a biopsy. Transrectal MRI provides detailed images to see if cancer may have spread outside the gland. For men with suspected spread, a PSMA PET scan can locate prostate cancer cells in lymph nodes, bone, or other organs. A diagnosis is confirmed with a biopsy, typically performed transrectally with ultrasound or MRI guidance. A pathologist examines the tissue and assigns a Gleason score, which describes how abnormal the cells look and how quickly the tumor is likely to grow. Scores range from 6 to 10, with 6 considered low-grade, 7 intermediate, and 8 to 10 high-grade. Staging combines PSA level, Grade Group derived from the Gleason score, and whether cancer is confined to the prostate or has extended to seminal vesicles, nearby tissues, lymph nodes, or distant sites such as bone. Treatment depends on stage, PSA, grade, age, overall health, and patient preferences. Options include active surveillance or watchful waiting for older men with low-risk disease or no symptoms, which involves close monitoring without immediate therapy. Definitive local treatments include surgery to remove the prostate and radiation therapy, including external beam and radiopharmaceutical approaches. Systemic treatments are used for more advanced disease and include hormone therapy to lower male hormones, chemotherapy, targeted therapy, immunotherapy, and bisphosphonate therapy to address bone metastases. New approaches such as cryosurgery, high-intensity focused ultrasound, and proton beam therapy are being studied in clinical trials.

• PSA blood test and digital rectal exam are initial tools, followed by imaging and biopsy for confirmation.
• Gleason score and Grade Group help predict how aggressive the cancer is and guide staging decisions.
• Treatment ranges from active surveillance to surgery, radiation, hormone therapy, chemotherapy, targeted therapy, and immunotherapy.

Related Topics

• Prostate Cancer Overview
• Prostate Cancer Screening
• Detection and Diagnosis

📌 Frequently Asked Questions

What are the early signs of prostate cancer?

Early prostate cancer may cause trouble starting urination, frequent urination especially at night, difficulty emptying the bladder completely, and a weak or interrupted urine stream. These symptoms can also be caused by noncancerous prostate enlargement, so medical evaluation is important.

References

1. National Cancer Institute. (2024). Prostate Cancer Treatment (PDQ®)–Patient Version. National Cancer Institute
2. National Cancer Institute. (2024). Prostate Cancer Prevention (PDQ®)–Patient Version. National Cancer Institute
3. American Cancer Society. (2025). Key Statistics for Prostate Cancer. American Cancer Society
4. Centers for Disease Control and Prevention. (2025). Screening for Prostate Cancer. CDC